DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/rhq9pr/epithelial)
has announced the addition of the “Epithelial
Ovarian Cancer – Pipeline Review, H2 2015” report to their
This report provides comprehensive information on the therapeutic
development for Epithelial Ovarian Cancer, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Epithelial Ovarian Cancer and special features on late-stage and
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development – 35 of the 60+
Companies Featured in this Pipeline Review
- AbbVie Inc.
Acceleron Pharma, Inc.
- Adaptimmune Limited
- Amgen Inc.
- Ascenta Therapeutics, Inc.
Astex Pharmaceuticals, Inc.
- AstraZeneca Plc
- Bayer AG
- Bionomics Limited
- Cerulean Pharma, Inc.
- Clovis Oncology, Inc.
- Dr. Reddy’s Laboratories Limited
- Eisai Co., Ltd.
- Genor BioPharma Co., Ltd.
- Glycotope GmbH
Hetero Drugs Limited
- ImmunoGen, Inc.
- Immunotope, Inc.
- Incyte Corporation
Innate Immunotherapeutics Limited
- Johnson & Johnson
- Mabion SA
- MabVax Therapeutics Holdings, Inc.
- Merck & Co., Inc.
- Millennium Pharmaceuticals, Inc.
- Mycenax Biotech Inc.
- Pfizer Inc.
- Pharma Mar, S.A.
- Pharmacyclics, Inc.
Prima BioMed Ltd.
- Tesaro, Inc.
For more information visit http://www.researchandmarkets.com/research/rhq9pr/epithelial
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716